Another case of PML hits the MS drug Tysabri
PML is a rare demylinating disease that occurs in 6 per 10 million patients. This is the third case that is associated with Tysabri. Investors are not happy.
ADVERTISEMENT
More in Uncategorized
Past Week
-
Your doctor saved your life but won’t return your call [PODCAST]
-
How corporate medicine is eroding truth and patient dignity
-
Why bipolar II is not just a milder version of bipolar I
-
Opt-out states and physician-led anesthesia care explained
-
How medical misinformation drives demand for nonscientific treatments
-
Bolus or drip? What the DOSE trial actually showed about heart failure [PODCAST]
-
Past 6 Months
-
I Googled my own name and a corporate clinic I’ve never worked at appeared [PODCAST]
-
Rethinking the role of family physicians vs. specialists
-
How corporate health care ruined the medical profession
-
Clinicians are failing at value-based care because no one taught them the system [PODCAST]
-
A humorous parody of medical specialties and the modern patient
-
When shared decision making gives way to medical paternalism
-
Recent Posts
-
Bolus or drip? What the DOSE trial actually showed about heart failure [PODCAST]
-
Accounts receivable days hide four billing problems
-
AI therapy chatbots are crossing into impersonation
-
The handwashing standard nobody finished. Until now.
-
Expanding the SOAP framework boosts health outcomes
-
How to navigate physician job loss in the first week
-
Subscribe to KevinMD and never miss a story!
Get free updates delivered free to your inbox.
